Authors: Esther S. Kim & Susan J. Keam
Abstract
Trilaciclib (COSELA™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of chemotherapy-induced myelosuppression (CIM) when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen in adults being treated for extensive-stage small cell lung cancer (ES-SCLC). It is the first approved therapy to provide myeloprotection, and when administered before chemotherapy, it is a valuable option for decreasing the incidence of CIM. In three clinical randomized trials, trilaciclib administration prior to standard-of-care chemotherapy for ES-SCLC reduced myelosuppression and the need for rescue interventions, improved patient-reported outcomes and the safety profile of the chemotherapy regimens, and had no impact on antitumor efficacy.
Adis evaluation of trilaciclib (COSELA™) for the reduction of chemotherapy-induced myelosuppression in the management of ES-SCLC |
First intravenous CDK 4/6 inhibitor approved to decrease the incidence of chemotherapy-induced myelosuppression (CIM) in patients with ES-SCLC |
Administered prior to chemotherapy |
Provides multilineage myeloprotection, reducing the need for supportive care interventions and dose delays/reductions and hospitalizations related to CIM and sepsis |
Provides improvements in patient-reported outcomes |
Improves overall safety profile of chemotherapy regimens |